ArticleNature communications2025
A long-term self-driven metronomic photodynamic system for cancer therapy.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Metronomic photodynamic therapy is a long-term, low-dose treatment strategy that employs optical devices with continuous photosensitizer administration and requires stable device attachment with a consistent power source. These factors significantly limit patient mobility. Currently, no metronomic photodynamic therapy modality can operate independent of external devices, underscoring the critical need for in vivo light sources that function without external energy inputs. In this study, we integrate self-luminous bacteria with a photosensitizer in alginate microcapsules to create a self-driven metronomic photodynamic therapy that can be securely implanted within a tumour, thereby enabling continuous light emission without requiring an external energy source or ongoing replenishment of photosensitive reactants. By harnessing nutrients from the tumour microenvironment, this system sustains the generation of reactive oxygen species. A single injection effectively eliminates larger tumours (>300 mm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.